Genelux Corporation (GNLX)
NasdaqCM · USD · Healthcare · Biotechnology
$2.05 (+7.33%) as of
Key statistics
- Market cap
- 92.75M
- Forward P/E
- -2.73
- EPS (TTM)
- -0.8600
- Dividend yield
- 0.00%
- 52-week range
- 1.8600 – 8.5350
- Beta
- 0.58
- Revenue (TTM)
- 8k
- Profit margin
- 0.00%
- Analyst target
- $18.83
- Volume
- 1.45M
About Genelux Corporation
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Westlake Village, CA, United States
- Employees
- 25
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.